← Back to Clinical Trials
Recruiting NCT07068490
Impact of Potassium Competitive Acid Blockers After Percutaneous Coronary Intervention for Efficacy and Safety Outcome: Target Trial Emulation Study.
Trial Parameters
Condition Coronary Artery Disease
Sponsor Samsung Medical Center
Study Type OBSERVATIONAL
Phase N/A
Enrollment 100,000
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-10-22
Completion 2025-12-31
Interventions
Routine use of P-CAB on DAPTGuideline Directed Medical Therapy
Brief Summary
Despite the fact that potassium competitive acid blocker (P-CAB) has been developed for the treatment of gastric ulcer or gastroesophageal reflux disease, the efficacy and safety of P-CAB for the use of gastrointestinal (GI) protection in patients undergoing percutaneous coronary intervention (PCI) and maintaining dual antiplatelet therapy (DAPT) remains uncertain.
Eligibility Criteria
Inclusion Criteria: * Patients who underwent PCI * Use of either clopidogrel, prasugrel, or ticagrelor in combination with aspirin * No use of PCAB, PPI, or an H2-receptor within the past month Exclusion Criteria: * Patients with low GI bleeding risk are taken on PPI * Patients with high GI bleeding risk do not take PPI